Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

A retrospective study of an artificial intelligence program for reading 3D mammography scans illustrated the pros, cons and ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

Days after the Women’s Health Initiative, one of the largest and longest women’s health studies in the world, announced that ...

Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer cell therapy program in ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...